Abstract
BackgroundTofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). Interim data (database not locked) from ≤24 months' participation (3 years' total treatment duration) for patients (pts)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have